RC
AVTX icon

RBF Capital’s Avalo Therapeutics AVTX Stock Holding History

RBF Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4
Closed -$24K – 371
2016
Q2 		$24K Buy
+4
New +$36.4K ﹤0.01% 364

Other funds holding AVTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

RBF Capital's AVTX Position: Q3 2016 in Review

RBF Capital sold out of Avalo Therapeutics (AVTX) in Q3 2016, closing a stake of 4 shares — an estimated $24K sold.

RBF Capital first reported a position in AVTX in Q2 2016 and held it in 1 quarter. The position peaked at $24K in Q2 2016. 4 funds tracked by Wall St. Rank hold AVTX as of Q3 2016.

  • RBF Capital reported no remaining Avalo Therapeutics position as of Q3 2016 after selling out during the quarter.
  • RBF Capital sold 4 Avalo Therapeutics shares in Q3 2016, an estimated $24K.
  • RBF Capital first reported a position in Avalo Therapeutics in Q2 2016 and held it in 1 quarter.
  • RBF Capital's Avalo Therapeutics position peaked at $24K in Q2 2016.
  • 4 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2016.

Based on RBF Capital's 13F filing for Q3 2016, filed 14 Nov 2016.